-
Trastuzumab Deruxtecan Plus Pertuzumab Improves PFS vs Standard Care in HER2+ Breast Cancer
02 Jun 2025 18:50 GMT
… breast cancer has been a taxane given with trastuzumab (Herceptin; Genentech … metastatic HER2-positive breast cancer to receive either … metastatic, HER2-positive breast cancer,” Tolaney said.
The … for HER2-positive metastatic breast cancer (CLEOPATRA): end-of …
-
Ribociclib Benefit Is Sustained in HR+ Early Breast Cancer Regardless of Age, Menopausal Status
01 Jun 2025 22:11 GMT
… positive, HER2-negative early breast cancer, according to an … , HER2-negative early breast cancer,” lead study author … HER2-negative early breast cancer across menopausal status and … #47;AstraZeneca, eFFECTOR Therapeutics, Genentech/Roche, Gilead Sciences …
-
Vepdegestrant may benefit certain patients with advanced breast cancer with ESR1 mutation
31 May 2025 19:56 GMT
… ER-positive, HER2-negative advanced breast cancer compared with fulvestrant, according to … with Arvinas, AstraZeneca, Daiichi Sankyo, Genentech/Roche, Gilead Sciences, … Bristol Myers Squib, Daiichi Sankyo, Genentech/Roche, Gilead Sciences, Incyte …
-
New data show Roche’s Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer
31 May 2025 18:49 GMT
… breast cancer
HR-positive breast cancer is the most prevalent type of all breast cancers … by 2045.
Genentech, in the … HER2– Metastatic Breast Cancer. Int J Breast Cancer. 2020;2020 … metastatic breast cancer. Presented at San Antonio Breast Cancer Symposium …
-
New Data Show Genentech’s Itovebi Significantly Extended Survival in a Certain Type of HR-positive Advanced Breast Cancer
31 May 2025 12:30 GMT
… breast cancer
HR-positive breast cancer is the most prevalent type of all breast cancers … .
About Genentech in Breast Cancer
Genentech has been advancing breast cancer research for … breast cancer, the most prevalent type of all breast cancers.
About Genentech …
-
T-DXd Rechallenge Is Safe After Grade 1 ILD in Breast Cancer and Other Solid Tumors
31 May 2025 02:10 GMT
… benefit in patients with breast cancer and other solid tumors … treatment options.
Within the breast cancer realm, T-DXd is … in this group had breast cancer (86%), and the … Pharma, Pfizer, Roche/Genentech, and Stemline Therapeutics.
References
Natsuhara …
-
Genentech’s Fenebrutinib Maintains Near-Complete Suppression of Disease Activity and Disability Progression for up to Two Years in People With Relapsing Multiple Sclerosis
30 May 2025 05:16 GMT
… potentially devastating diseases.
Genentech and Roche are … neuroscience today.
About Genentech Access Solutions
Access … cancers (malignancies) including breast cancer: Follow your healthcare provider … screening guidelines for breast cancer.
Inflammation of the …
-
Personalized Medicine Market Set to Soar Beyond US$650 Billion by 2025 | DataM Intelligence
04 Jun 2025 12:31 GMT
… in Action: Transforming Patient Care
Breast Cancer
An early example of an … authorized treatment for HER2-positive breast cancer, which affects approximately 30% of … 2025: Roche Diagnostics partnered with Genentech to co-develop companion diagnostics …
-
BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
02 Jun 2025 10:56 GMT
… the candidate in triple negative breast cancer (“TNBC”) is planned to start … ”) and first-line triple-negative breast cancer (“TNBC”). Additional trials will explore … Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche …
-
BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
02 Jun 2025 10:45 GMT
… the candidate in triple negative breast cancer (“TNBC”) is planned to start … ”) and first-line triple-negative breast cancer (“TNBC”). Additional trials will explore … Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche …
About
© 1995-2025